Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Hematologic Malignancies Treatment Market size was estimated at $99.55 Billion, projected to grow at a CAGR of 9.73% - Brandessence Market Research

This image opens in the lightbox

News provided by

Brandessence Market Research And Consulting Private Limited

10 Nov, 2022, 11:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Nov. 10, 2022 /PRNewswire/ -- According to the latest market research, The Global Hematologic Malignancies Treatment Market is valued at US$ 51.97 Billion in 2021, and it is expected to reach US$ 99.55 Billion by 2028, with a CAGR of 9.73% during the forecast period of 2022-2028.

Hematologic malignancy is referred to as a type of cancer which is formed in blood-producing tissues like the bone marrow. It predominantly infects the blood, bone marrow, along with lymph nodes, thereby affecting the entire immune system of the patient. These cancer forms generally occur due to the unregulated growth of abnormal blood cells which in turn prevents the development of regular blood cells and hinders their functions. Hematologic malignancies are bifurcated into three primary categories, namely myeloma, leukemia, and lymphoma.

Get Sample of Report@ https://brandessenceresearch.com/requestSample/PostId/2112

Global Hematologic Malignancies Treatment Market Insights (2022-2028)

The widespread development in the field of medical science has led to the advent of various effect treatment procedures aimed at curing hematologic malignancies. Chemotherapy, bone marrow transplantation, immunotherapy, along with CAR T cell therapy, just to name a few are some of the most frequently recommended procedures to treat this type of disorders.

Growing prevalence of cancer worldwide, rising healthcare expenditure, and rising R&D activities in the field are primarily augmenting the outlook of this business vertical.

Also, surging health cognizance of the masses, increase in the geriatric population base, along with rising disposable income of the individuals are adding momentum to the expansion of this marketplace.

Furthermore, increasing number of oncologists across the globe, growing efforts by key players to develop advanced treatment therapeutics in the field, along with escalating demand for early diagnosis of cancer are creating lucrative opportunities for this industry vertical to prosper.

Besides, rising instances of new drug approvals along with growing government initiatives to spread cancer awareness among the masses are aiding market expansion.

On the contrary, high cost pertaining to blood cancer treatment therapeutics is hindering the remuneration scope for global hematologic malignancies treatment market.

Competitive Hierarchy

The prominent players characterizing the competitive terrain of this industry vertical are AbbVie Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and others.

These companies are extending their global footprint by formulating organic and inorganic business growth strategies. They are focused towards enhancing their remuneration scope by engaging in product launches, mergers & acquisitions, R&D investments, and collaborations, among others.

Hematologic Malignancies Treatment Market: Segmentation Analysis

By Condition:

  • Lymphoma
  • Leukemia
  • Myeloma

By Therapy:

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Others

By End-User:

  • Medical Stores
  • Hospital Pharmacies
  • E-Commerce Platform

Get Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/2112

Region-wise Outlook

Which is the fastest growing region in this business vertical?

North America has been witnessing a prompt development over the stipulated timeline. This is attributable to the growing pervasiveness of blood cancer, increasing healthcare expenditure, and rising R&D investments in the field.

Also, rapidly evolving healthcare expenditure, presence of noteworthy players, surging number of clinical trials, along with increasing geriatric population base.

What is Asia Pacific's position in the global hematologic malignancies treatment market?

Asia Pacific is reckoned to garner significant returns over the forecast period owing to the increasing government efforts to raise cancer awareness, escalating demand for early disease diagnosis, adoption of unhealthy lifestyle habits by the masses, along with growing R&D activities in the field.

Category-wise Insights

Which condition segment presently leads the industry?

The leukemia segment is amassing notable gains over the assessment timeline due to the growing pervasiveness of this condition in children under 15 and in older people over 55 years of age. It is regarded as one of the fastest spread cancer which begins in the bone marrow.

Which therapy segment holds the most dominant position in the market?

The chemotherapy segment presently dominates the industry in terms of volume share. This is credited to the increasing incidence of blood cancer worldwide and the efficacy of this treatment procedure in treating different forms of cancer.

Which end user segment is witnessing robust growth in the business vertical?

The hospital segment has been generating a significant revenue share owing to the presence of adequate treatment infrastructure and skilled professions in hospitals. Moreover, surge in healthcare expenditure along with increasing patient pool is further contributing to the segmental development.

Market growth comparison pertaining to the historical years and forecast timeline of 2022-2028

The marketplace has been registering notable gains over the stipulated timeline owing to the emergence of various growth inducing factors.

There has been a growing prevalence of hematologic malignancies around the globe. This is powered by the rising geriatric population base along with unhealthy lifestyle of the masses, among others. Therefore, the need for efficient therapeutics in the field has surged over the forecast duration.

The increasing awareness pertaining to the early diagnosis of cancer so as to facilitate early treatment and reduce mortality rate are stimulating the overall dynamics of this business vertical.

The field of medical science is witnessing widespread advancements in the field of immunochemistry. This is enabling healthcare professionals to accurately identify hematologic malignancies by unveiling tissue samples to various antibodies that are directed against antigens and molecules.

Governments across the globe have increased their efforts to improve healthcare facilities in the respective nations. This will further accelerate cancer based research activities and facilitate the development of new and effective therapeutics in the field. This in turn is anticipated to propel the growth of global hematologic malignancies treatment market.

On Special Requirement Hematologic Malignancies Treatment Market Report is also available for below region:

North America

  • U.S, Canada

Europe

  • Germany, France, U.K., Italy, Spain, Sweden, Netherland, Turkey, Switzerland, Belgium, Rest of Europe

Asia-Pacific

  • South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC

Latin America

  • Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America

Middle East and Africa

  •  Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA

Major Developments

  •  In October 2022, AstraZeneca Pharma India announced the launch of its Acalabrutinib 100 mg capsules. This drug is being used during the treatment of various blood cancer forms and is said to be quite effective.

Purchase Copy of Report @ https://brandessenceresearch.com/Checkout?report_id=2112

Related Reports:

  • Induction Cooktops Market Size is Anticipated to Reach a USD 36.38 Bn by 2028, Share, Size, Future Trends, Demand, Growth Statistics, Competitive Analysis and Segmentation Analysis | Brandessence Market Research
  • Global Stem Cell Therapy Market Size to Reach USD 554.25 Million by 2028: Brandessence Market Research
  • Global Diabetes Care Devices Market Size to register 8.1% CAGR through 2028 | Brandessence Market Research
  • Ceramic Fiber Market Worth USD 4432.5 Million by 2028 at a CAGR of 9.8% - Report by Brandessence Market Research
  • Healthcare Revenue Cycle Management Market worth $ 222.57 Billion by 2028 - Exclusive Report by Brandessence Market Research
  • Solid Tumor Treatment Market Size Worth USD 310.49 Billion by 2028| Brandessence Market Research
  • Sunitinib Malate Market Growth Trends 2022 Latest Challenges, Recent Opportunities, Emerging Technologies, Business Share and Size Forecast to 2028
  • Thalassemia Treatment Market – Industry Trends and Forecast to 2028
  • Depression Drugs Market is Booming with a Large Industrial Scope | Report Analysis on Expansion, Share, Revenue, Latest and Future Trends (2022-2028)
  • Prostate Cancer Diagnosis And Treatment Market Size Worth USD 10.03 Billion by 2028 at 12.5% CAGR – Report by Brandessence Market Research

i-Factor: Live Market intelligence platform 

I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister 

Brandessence Market Research & Consulting Pvt ltd. 

Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London. 

Follow Us: Linkedin Blog: Menopause Treatment Market Companies

Contact: 
Mr. Vishal Sawant  
Email: vishal@brandessenceresearch.com  
Email: Sales@brandessenceresearch.com  
Corporate Sales: +44-2038074155  
Asia Office: +917447409162 

Logo: https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.